Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea
· Delayed Price · Currency is KRW 28,300
-500 (-1.74%)
At close: Mar 28, 2025, 3:30 PM KST
Hanall Biopharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -1,805 | 3,509 | 251.47 | 8,896 | 19,764 | Upgrade
|
| Depreciation & Amortization | 3,121 | 3,247 | 3,053 | 2,725 | 2,894 | Upgrade
|
| Loss (Gain) From Sale of Assets | 452.56 | 9.32 | -16.99 | 1,052 | 14.29 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 36.72 | - | - | 44.82 | Upgrade
|
| Loss (Gain) From Sale of Investments | -331.43 | -1,121 | 625.15 | 177.44 | - | Upgrade
|
| Loss (Gain) on Equity Investments | 99.53 | 62.12 | 45.39 | - | - | Upgrade
|
| Stock-Based Compensation | 584.26 | 1,623 | 1,875 | 1,617 | 794.3 | Upgrade
|
| Provision & Write-off of Bad Debts | -126.7 | 50.6 | 61.23 | -21.9 | -126.79 | Upgrade
|
| Other Operating Activities | 3,819 | 2,044 | 4,516 | 1,694 | -9,049 | Upgrade
|
| Change in Accounts Receivable | 2,367 | 8,168 | -2,466 | -5,919 | 4,306 | Upgrade
|
| Change in Inventory | -5,748 | -8,292 | -5,814 | -1,476 | -8,435 | Upgrade
|
| Change in Accounts Payable | -127.23 | 5,518 | 3,361 | -1,731 | 646.63 | Upgrade
|
| Change in Other Net Operating Assets | 7,055 | 14,789 | 19,774 | -6,174 | -9,924 | Upgrade
|
| Operating Cash Flow | 9,360 | 29,643 | 25,264 | 839.87 | 929.29 | Upgrade
|
| Operating Cash Flow Growth | -68.42% | 17.33% | 2908.10% | -9.62% | -95.47% | Upgrade
|
| Capital Expenditures | -1,642 | -2,412 | -2,830 | -4,606 | -2,562 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 17 | 120.91 | 1.5 | Upgrade
|
| Sale (Purchase) of Intangibles | -21,427 | -6,786 | -4,847 | -4,396 | -4,827 | Upgrade
|
| Investment in Securities | -4,125 | -2,676 | -2,932 | 16,911 | 5,070 | Upgrade
|
| Other Investing Activities | -0 | -0 | - | -0 | -0 | Upgrade
|
| Investing Cash Flow | -27,493 | -11,887 | -10,592 | 8,030 | -2,318 | Upgrade
|
| Long-Term Debt Repaid | -942.18 | -813.51 | -698.88 | -715.25 | -587.67 | Upgrade
|
| Total Debt Repaid | -942.18 | -813.51 | -698.88 | -715.25 | -587.67 | Upgrade
|
| Net Debt Issued (Repaid) | -942.18 | -813.51 | -698.88 | -715.25 | -587.67 | Upgrade
|
| Issuance of Common Stock | 1,702 | - | - | 408.72 | 68.33 | Upgrade
|
| Repurchase of Common Stock | - | - | -10,005 | - | - | Upgrade
|
| Financing Cash Flow | 759.59 | -813.51 | -10,704 | -306.53 | -519.35 | Upgrade
|
| Foreign Exchange Rate Adjustments | 36.83 | -60.45 | 78.63 | 30.85 | -11.85 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | 0 | - | - | - | Upgrade
|
| Net Cash Flow | -17,336 | 16,882 | 4,047 | 8,594 | -1,920 | Upgrade
|
| Free Cash Flow | 7,718 | 27,231 | 22,434 | -3,766 | -1,633 | Upgrade
|
| Free Cash Flow Growth | -71.66% | 21.38% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 5.56% | 20.18% | 20.39% | -3.71% | -1.84% | Upgrade
|
| Free Cash Flow Per Share | 152.20 | 537.18 | 441.48 | -73.55 | -31.91 | Upgrade
|
| Cash Interest Paid | 70.97 | 63.86 | 39.45 | - | - | Upgrade
|
| Cash Income Tax Paid | 782.26 | 1,017 | 606.84 | 1,695 | 1,826 | Upgrade
|
| Levered Free Cash Flow | -26,378 | 4,850 | -17,027 | -665.94 | -4,687 | Upgrade
|
| Unlevered Free Cash Flow | -26,333 | 4,890 | -17,014 | -650.01 | -4,677 | Upgrade
|
| Change in Net Working Capital | 6,546 | -9,751 | 13,330 | 684.72 | 4,019 | Upgrade
|
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.